![rapt stock forecast rapt stock forecast](https://www.philadelphiafed.org/-/media/frbp/assets/surveys-and-data/regional-charts/emp.png)
![rapt stock forecast rapt stock forecast](https://i1.wp.com/playcrazygame.com/wp-content/uploads/2021/09/22fev2020-bolsa-de-valores-acoes-da-petrobras-despencaram-quase-20-no-ibovespa-apos-anuncio-de-troca-no-comando-da-estatal-1614026413672_v2_615x300.jpg)
Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Rapt Therapeutics was mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Rapt Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Rapt Therapeutics shares have added about 93.8% since the beginning of the year versus the S&P 500's gain of 24.7%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The company has not been able to beat consensus revenue estimates over the last four quarters. This compares to year-ago revenues of $1.53 million. Rapt Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.97 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 33.38%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. A quarter ago, it was expected that this company would post a loss of $0.62 per share when it actually produced a loss of $0.63, delivering a surprise of -1.61%. This quarterly report represents an earnings surprise of -5%. These figures are adjusted for non-recurring items. This compares to loss of $0.60 per share a year ago.
#Rapt stock forecast free#
Rapt Therapeutics ( RAPT Quick Quote RAPT - Free Report) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.60.